\n\n

A new OpenAI life‑sciences model, gpt‑rosalind‑discovery, has quietly appeared on the API pricing page, signaling the company’s deeper push into vertical AI markets. The model, launched …

\n\n

The AI‑driven drug discovery landscape is heating up on three fronts: new specialised models, virtual trial simulations that are increasingly accurate, and the first generative‑AI‑designed drugs …

\n\n

Key developments this week include a projected market surge to $17.6 billion by 2031, a $7.7 billion informatics outlook for 2030, and unprecedented activity from frontier AI labs. …

\n\n

The AI‑drug discovery market is set to explode, with forecasts showing a jump from $5.09 billion in 2026 to $17.56 billion by 2031, a 28.1% annual growth rate. …